







Silicon Valley efforts in the biology and health domains have recently seen increased public interest because of the questions around the legitimacy of Theranos' technology and medical claims and the recent FDA approvals for a number of 23andMe's genetic screens. These data points are just two of the most visible examples of a broad ecosystem of companies and startups in Silicon Valley working on biological problems.
Biotech boot camp
US funding agencies are turning to a Silicon Valley entrepreneur to focus fledgling biomedical companies on success — even when that means making a scientific course correction.

Humans: The Next Platform | TechCrunch
Biohacking and transhumanist advances (including nootropics, extended longevity, cybernetic implants, better behavioral and genetic self-understanding) will materially advance our quality of life and productivity in the coming decade, but we need to be thoughtful about the potential social and ethical pitfalls as we transform. Google Trends shows a marked uptick in searches for “nootropics” and related biohacking fields, so now is the time to have the conversation about the direction we’re headed.

Eugenics, Environmental Ruin, and Surveillance: The Story of Silicon Valley
California’s tech industry cannot escape its original sins.

The SXSW ecosystem is embracing a biotech wave
A look at the expanding biotech landscape at SXSW.

Is Silicon Valley Investing in the Wrong Stuff?
Keywords: Silicon Valley appears to have given up on solving anything but its own problems: those afflicting the same 20-somethings who are building these startups. The problem lies with venture capitalists, not entrepreneurs.

A Look Inside Silicon Valley's Wild Biotech Accelerator IndieBio | TechCrunch
Silicon Valley breeds the kind of people that create computers that fit in the palm of our hands, electric cars that can go hundreds of miles on a single

Looking for the future of technology among the startup strivers
The new company men of Silicon Valley

Genomics Needs A Killer App | TechCrunch
Genomics has undergone a major shift in the last year. The drop in price in the past decade from $3B to $1K to sequence a genome is the 10X force likely to cause an inflection point in a number of health-related industries. But despite the price, right now genomics is a niche product in large part used in and promoted by academia.

The Rise of the Silicon Valley Small Business
What you need to know about the next big startup archetype
Why Silicon Valley is bringing eugenics back
Elon Musk is the most prominent face of the effort to protect tech's privilege

How Biotech Startup Funding Will Change in the Next 10 Years | Y Combinator
Back when YC was getting started about 10 years ago, Paul Graham wrote some [http://www.paulgraham.com/webstartups.html] essays [http://www.paulgraham.com/future.html] that predicted the way startup fundraising would change in the next decade – accurately, it turns out. Paul Graham predicted that there would be way more startups, that they’d be cheaper to start, that new kinds of investors would fund them, that founders would be more technical, and that founders would keep control of their compa
Tech Billionaires Need to Stop Trying to Make the Science Fiction They Grew Up on Real
Today’s Silicon Valley billionaires grew up reading classic American science fiction. Now they’re trying to make it come true, embodying a dangerous political outlook

The Story behind the Science: Preprints of pandemic potential—how bioRxiv and medRxiv brought preprints to the life sciences
ABSTRACT The bioRxiv and medRxiv preprint servers brought preprinting to the life sciences and played a critical role in disseminating COVID research during the pandemic. Here, I reflect on the birth of bioRxiv and medRxiv and the crucial role so many members of the community played, our experience during the pandemic, and the launch of the new non-profit organization set up to oversee the servers. The pandemic was a stress test for bioRxiv and medRxiv that demonstrated their value and robustness. Under the umbrella of openRxiv, they are now poised to become long-term infrastructure underpinning a new publishing ecosystem.

‘I think it is actively happening’: Is Boston’s biotech industry doomed? - The Boston Globe
With a "terrible" job market, empty labs, and mounting competition from China, the lifeblood of Kendall Square is under massive threat.

Sentinel Bio
Established as a non-profit philanthropic fund, Sentinel Bio finds, funds, and scales solutions to prevent biosecurity risks and respond to pandemics, reducing threats to health and economic stability worldwide.
